Inside "Drug Reference":

@CancerQuest on Twitter:

Related to this page:

Was this page helpful? | What did you like most? How can we make it better?

CancerQuest > Drugs > Panitumumab (Vectibix®)

Panitumumab (Vectibix®)

Generic Name: Panitumumab Brand Name(s): Vectibix® IUPAC: http://www.cancerquest.org/multimedia/images/drugs/dp-antibody-general.jpg FDA Approval: yes Manufacturer Link

Usage: Currently panitumumab is approved for the treatment of EGFR-expressing, metastatic colorectal cancer that has progressed after other chemotherapy regimens, including fluoropyrimidine, oxaliplatin and irinotecan.

Mechanism: Panitumumab (Vectibix®) is a human-derived monoclonal antibody that binds to the human epidermal growth factor receptor (EGFR). When EGFR is activated, it acts as a tyrosine kinase to activate proteins within the cell, leading to the growth, movement and transformation of cells. EGFR is often overexpressed in cancer cells, leading to excessive cell proliferation. Panitumumab blocks the activation of EGFR, inhibiting its ability to activate other proteins. Note that the image shown is a general structure of an antibody. There are four proteins bound together in a 'Y' shape. The two top tips of the Y are where the antibody binds with its target. This means that each antibody molecule can bind to two identical target regions.

Side Effects: Side Effects include: Low electrolyte levels, Nausea, vomiting, constipation and/or diarrhea, Fatigue

Contraindications: Serious effects that can result from panitumumab treatment include dermatologic toxicity including dermatitis acneiform, redness, paronychia (infection at the base of the fingernail or toenail), rash, skin exfoliation, dry skin and skin fissures; infusion reactions (anaphylactic shock, bronchospasm, fever, chills and low blood pressure); and pulmonary fibrosis. Due to a potential harm to the developing fetus, women receiving this treatment should take contraceptive measures and pregnant women should be warned of this risk. New mothers should not nurse infants during or immediately following this treatment regimen. Panitumumab is not recommended for use in combination chemotherapy regimens. Since sunlight can enhance skin reactions due to panitumumab, patients should limit sun exposure during treatment.